Xponance’s Rigel Pharmaceuticals RIGL Stock Holding History

Xponance’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,012	Closed	-$15K	–	1359
2024 Q1	$15K	Hold	1,012	–	–	﹤0.01%	1302
2023 Q4	$14.7K	Buy	+1,012	New	+$10.3K	﹤0.01%	1272

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Xponance's RIGL Position: Q2 2024 in Review

Xponance sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 1,012 shares — an estimated $15K sold.

Xponance first reported a position in RIGL in Q4 2023 and held it in 2 quarters. The position peaked at $15K in Q1 2024. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

Xponance reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Xponance sold 1,012 Rigel Pharmaceuticals shares in Q2 2024, an estimated $15K.
Xponance first reported a position in Rigel Pharmaceuticals in Q4 2023 and held it in 2 quarters.
Xponance's Rigel Pharmaceuticals position peaked at $15K in Q1 2024.
91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Xponance's 13F filing for Q2 2024, filed 14 Aug 2024.